Want to see CH:SHLTN full AI Analyst Report?
Top Page
Shl Telemedicine
(SHLTN)
Select Model
Select Model
Rating:44Neutral
Price Target:
CHF1.00
Action:Reiterated
Date:06/30/26
The score is driven primarily by weak financial performance: ongoing net losses and persistent negative operating/free cash flow are the main risks. The balance sheet is relatively more stable with moderate leverage, but that support is offset by the cash burn. With no usable technical indicators and valuation constrained by a negative P/E and missing dividend yield, there are limited offsetting positives in the available data.
Positive Factors
Balance-sheet support
Moderate leverage and declining total debt alongside higher equity in 2025 provide a structural buffer versus peers. This improves financial flexibility, reduces near-term refinancing risk and lengthens runway, enabling strategic investment or restructuring while losses are addressed.
Negative Factors
Persistent net losses
Ongoing and worsening net losses erode retained earnings and limit reinvestment capacity. Over months this reduces strategic optionality, raises dependency on external capital, and risks balance-sheet deterioration if profitability is not restored to a sustainable level.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet support
Moderate leverage and declining total debt alongside higher equity in 2025 provide a structural buffer versus peers. This improves financial flexibility, reduces near-term refinancing risk and lengthens runway, enabling strategic investment or restructuring while losses are addressed.
Read all positive factors
Shl Telemedicine (SHLTN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF39.65M
Dividend YieldN/A
Average Volume (3M)15.43K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue Growth-2.63%
EPS Growth40.87%
CountryCH
Employees526
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.71
Shares Outstanding37,059,944
10 Day Avg. Volume8,507
30 Day Avg. Volume15,434
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.73
Price to Sales (P/S)0.52
P/FCF Ratio-9.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Shl Telemedicine Business Overview & Revenue Model
Company Description
Established in 1987 and headquartered in Tel Aviv, Israel, SHL Telemedicine Ltd. is a global provider specializing in the development and distribution of individual remote healthcare solutions across Israel, Europe, and other international markets...
How the Company Makes Money
null...
Shl Telemedicine Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
60
Neutral
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 61.49M | 56.78M | 57.08M | 59.00M | 49.58M |
| Gross Profit | 22.89M | 25.79M | 25.26M | 27.19M | 24.59M |
| EBITDA | 3.28M | -18.15M | 3.02M | 9.48M | 4.35M |
| Net Income | -16.11M | -28.09M | -7.06M | -76.00K | -14.11M |
Balance Sheet | |||||
| Total Assets | 84.56M | 80.76M | 113.05M | 110.78M | 129.59M |
| Cash, Cash Equivalents and Short-Term Investments | 25.26M | 17.52M | 26.25M | 18.70M | 32.06M |
| Total Debt | 13.08M | 16.12M | 19.86M | 26.74M | 32.50M |
| Total Liabilities | 40.82M | 41.51M | 36.59M | 51.49M | 68.83M |
| Stockholders Equity | 43.74M | 39.25M | 73.53M | 55.69M | 56.85M |
Cash Flow | |||||
| Free Cash Flow | -3.48M | -4.04M | -6.99M | -1.73M | -3.07M |
| Operating Cash Flow | -1.90M | -372.00K | -1.50M | -73.00K | 185.00K |
| Investing Cash Flow | 7.93M | 6.03M | -9.35M | -6.43M | -40.97M |
| Financing Cash Flow | 11.02M | -4.87M | 13.67M | -2.28M | 51.08M |
Shl Telemedicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
Shl Telemedicine Corporate Events
SHL Telemedicine Wins Renewed Israeli Defense Contract on Tougher Terms
Jun 24, 2026
SHL Telemedicine’s subsidiary Mediton has secured a new three-year exclusive contract to continue providing services to the Rehabilitation Department of the Israeli Ministry of Defense, with an option for the MOD to extend the engagement by ...
SHL Telemedicine Sets AGM to Vote on Governance and Executive Option Changes
Jun 22, 2026
SHL Telemedicine has called its Annual General Meeting for July 16, 2026 in Tel Aviv, where shareholders will review 2025 results and vote on the reappointment of its external auditor and the election or re-election of board members, including a n...
SHL Telemedicine Narrows Loss and Bolsters Balance Sheet as Turnaround Advances
Mar 31, 2026
SHL Telemedicine reported 2025 revenues of USD 59 million, broadly stable year-on-year, while lifting gross margin to 47% and cutting its net loss to USD 15.4 million as restructuring gains and sharply lower one-off charges took effect. Adjusted E...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.